NASDAQ:OCAT - Ocata Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.47 +8.47 (+∞)
(As of 02/11/2016)
Previous Close$8.47
Today's Range$8.47 - $8.47
52-Week Range$3.06 - $8.71
VolumeN/A
Average Volume656,469 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive OCAT News and Ratings via Email

Sign-up to receive the latest news and ratings for OCAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:OCAT
Previous SymbolOTCMKTS:ACTC
CUSIPN/A
Phone+1-508-7561212

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Ocata Therapeutics (NASDAQ:OCAT) Frequently Asked Questions

What is Ocata Therapeutics' stock symbol?

Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."

How were Ocata Therapeutics' earnings last quarter?

Ocata Therapeutics Inc (NASDAQ:OCAT) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $0.04 million during the quarter. View Ocata Therapeutics' Earnings History.

Has Ocata Therapeutics been receiving favorable news coverage?

News coverage about OCAT stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ocata Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the next several days.

What other stocks do shareholders of Ocata Therapeutics own?

How do I buy shares of Ocata Therapeutics?

Shares of OCAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocata Therapeutics' stock price today?

One share of OCAT stock can currently be purchased for approximately $8.47.

What is Ocata Therapeutics' official website?

The official website for Ocata Therapeutics is http://www.ocata.com.

How can I contact Ocata Therapeutics?

Ocata Therapeutics' mailing address is 33 Locke Dr, MARLBOROUGH, MA 01752-1167, United States. The biotechnology company can be reached via phone at +1-508-7561212.


MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe OCAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: LIBOR

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel